U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07114367) titled 'NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma' on July 03.
Brief Summary: This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Non Hodgkin Lymphoma (NHL)
Intervention:
DRUG: NB02 (Poseltinib)
Dose Level 1, Dose Level 2, Dose Level 3
Recruitment Status: NOT_YET_RECRUITING
Sponsor: NOBO Medicine
Published by HT Digital Conte...